Unaudited Financial Results 31-12-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Crestchem Ltd reported Q3 FY26 revenue from operations of Rs 715.82 lakhs, up 49.2% YoY from Rs 479.59 lakhs in Q3 FY25, driven by its single Nutrition-Speciality Chemicals segment. For the nine months ended Dec 2025, revenue grew 8.6% YoY to Rs 1,938.21 lakhs. Q3 profit after tax jumped 37.6% YoY to Rs 71.71 lakhs, but 9M PAT actually fell about 24% to Rs 161.31 lakhs from Rs 211.61 lakhs, as total expenses rose faster than revenue. EBITDA margins clearly compressed, with 9M operating margin slipping from roughly 16% to around 11%, reflecting higher material and employee costs. Q3 EPS stood at Rs 2.39. The statutory auditor issued an unqualified (clean) limited review report.
Short-term, the strong 49% Q3 revenue jump and PAT growth are positive, but the 24% drop in 9M profits and clear margin compression indicate rising costs that investors should watch closely. Mixed signals — likely neutral to mildly negative on the stock until cost pressures ease.